Aegerion Pharmaceuticals Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Cowen Cuts Price Target on Aegerion Pharma (AEGR) Following 3Q Results
November 10, 2015 8:35 AM ESTCowen maintained a Market Perform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $15.00 (from $25.00), following the company's 3Q earnings report. Juxtapid sales were $58.8MM, ahead of consensus of $54MM. Myalept revenue of $8.5MM was ahead of consensus of... More
Aegerion Pharma (AEGR) Tops Q3 EPS by 8c
November 9, 2015 4:22 PM ESTAegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.
Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.
For... More
